Literature DB >> 1861635

Insulin resistance in multiple aspects of intermediary metabolism in myotonic dystrophy.

A J Krentz1, A C Williams, M Nattrass.   

Abstract

The responses of circulating intermediary metabolites to a low-dose incremental insulin infusion (basal, 0.005, 0.01, and 0.05 U.kg-1.h-1) were examined in eight ambulant subjects with the multisystem disorder, myotonic dystrophy. Eight healthy subjects matched for age, gender, and body mass index served as controls. Oral glucose tolerance (75 g) was normal in all subjects. Basal (postabsorptive) hyperinsulinemia was observed in the subjects with myotonic dystrophy (8.4 +/- 2.0 v 2.3 +/- 0.2 mU/L, P less than .01) with increased basal C-peptide levels. Basal blood glycerol (0.09 +/- 0.02 v 0.05 +/- 0.01 mmol/L, P less than .05), lactate (1.14 +/- 0.12 v 0.77 +/- 0.07 mmol/L, P less than .02), and pyruvate (0.08 +/- 0.01 v 0.05 +/- 0.01 mmol/L, P less than .02) were also elevated in these subjects. During the incremental insulin infusion, circulating insulin (F = 8.2, P less than .02) and C-peptide (F = 5.1, P less than .05) levels were significantly higher in the myotonic subjects. Despite the hyperinsulinemia, circulating concentrations of lactate (F = 9.8, P less than .01), pyruvate (7.8, P less than .02), and glycerol (F = 7.5, P less than .02) were also higher in the subjects with myotonic dystrophy, providing prima facie evidence of insulin resistance in the regulation of these metabolites. During the highest insulin rate, isotopically determined metabolic clearance rate of glucose was significantly lower in the myotonic subjects (3.6 +/- 0.4 v 5.5 +/- 0.7 mL.kg-1.min-1, P less than .05), indicating impaired peripheral glucose metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861635     DOI: 10.1016/0026-0495(91)90017-q

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  Hyperproinsulinaemia in patients with myotonic dystrophy.

Authors:  A J Krentz; P M Clark; L Cox; A C Williams; M Nattrass
Journal:  Diabetologia       Date:  1992-12       Impact factor: 10.122

2.  Study on growth hormone and insulin secretion in myotonic dystrophy.

Authors:  J M Gómez Sáez; J M Fernández Real; M Fernández Castañer; M A Navarro Moreno; J A Martínez Matos; J Soler Ramón
Journal:  Clin Investig       Date:  1994-07

3.  Muscleblind-like 3 deficit results in a spectrum of age-associated pathologies observed in myotonic dystrophy.

Authors:  Jongkyu Choi; Donald M Dixon; Warunee Dansithong; Walid F Abdallah; Kenneth P Roos; Maria C Jordan; Brandon Trac; Han Shin Lee; Lucio Comai; Sita Reddy
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.